These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1510386)

  • 21. Biochemistry of Parkinson's disease with special reference to the dopaminergic systems.
    Hirsch EC
    Mol Neurobiol; 1994; 9(1-3):135-42. PubMed ID: 7888089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding cell death in Parkinson's disease.
    Jenner P; Olanow CW
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S72-84. PubMed ID: 9749577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study.
    Good PF; Olanow CW; Perl DP
    Brain Res; 1992 Oct; 593(2):343-6. PubMed ID: 1450944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuromelanin and Parkinson's disease.
    Marsden CD
    J Neural Transm Suppl; 1983; 19():121-41. PubMed ID: 6321645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanoscale synchrotron x-ray analysis of intranuclear iron in melanised neurons of Parkinson's substantia nigra.
    Brooks J; Everett J; Hill E; Billimoria K; Morris CM; Sadler PJ; Telling N; Collingwood JF
    Commun Biol; 2024 Aug; 7(1):1024. PubMed ID: 39164395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glutathione peroxidase, glial cells and Parkinson's disease.
    Damier P; Hirsch EC; Zhang P; Agid Y; Javoy-Agid F
    Neuroscience; 1993 Jan; 52(1):1-6. PubMed ID: 8433802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease.
    Olanow CW
    Mov Disord; 1993; 8 Suppl 1():S1-7. PubMed ID: 8302302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Iron and ferritin in substantia nigra in Parkinson's disease.
    Jellinger KA; Kienzl E; Rumpelmaier G; Paulus W; Riederer P; Stachelberger H; Youdim MB; Ben-Shachar D
    Adv Neurol; 1993; 60():267-72. PubMed ID: 8420142
    [No Abstract]   [Full Text] [Related]  

  • 30. In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease.
    Gonzalez-Sepulveda M; Compte J; Cuadros T; Nicolau A; Guillard-Sirieix C; Peñuelas N; Lorente-Picon M; Parent A; Romero-Giménez J; Cladera-Sastre JM; Laguna A; Vila M
    Brain; 2023 Mar; 146(3):1040-1052. PubMed ID: 36717986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
    Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
    Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea.
    Waters CM; Peck R; Rossor M; Reynolds GP; Hunt SP
    Neuroscience; 1988 May; 25(2):419-38. PubMed ID: 2456487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preservation of midbrain catecholaminergic neurons in very old human subjects.
    Kubis N; Faucheux BA; Ransmayr G; Damier P; Duyckaerts C; Henin D; Forette B; Le Charpentier Y; Hauw JJ; Agid Y; Hirsch EC
    Brain; 2000 Feb; 123 ( Pt 2)():366-73. PubMed ID: 10648443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.
    Hirsch E; Graybiel AM; Agid YA
    Nature; 1988 Jul; 334(6180):345-8. PubMed ID: 2899295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An introduction to the free radical hypothesis in Parkinson's disease.
    Olanow CW
    Ann Neurol; 1992; 32 Suppl():S2-9. PubMed ID: 1510376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease.
    Pearce RK; Owen A; Daniel S; Jenner P; Marsden CD
    J Neural Transm (Vienna); 1997; 104(6-7):661-77. PubMed ID: 9444566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.
    Zecca L; Casella L; Albertini A; Bellei C; Zucca FA; Engelen M; Zadlo A; Szewczyk G; Zareba M; Sarna T
    J Neurochem; 2008 Aug; 106(4):1866-75. PubMed ID: 18624918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?
    Ling H; Kearney S; Yip HL; Silveira-Moriyama L; Revesz T; Holton JL; Strand C; Davey K; Mok KY; Polke JM; Lees AJ
    J Neurol Neurosurg Psychiatry; 2016 Jun; 87(6):633-41. PubMed ID: 26209716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour.
    Zecca L; Tampellini D; Gerlach M; Riederer P; Fariello RG; Sulzer D
    Mol Pathol; 2001 Dec; 54(6):414-8. PubMed ID: 11724917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis.
    Hirsch EC; Brandel JP; Galle P; Javoy-Agid F; Agid Y
    J Neurochem; 1991 Feb; 56(2):446-51. PubMed ID: 1988548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.